Cresco Labs Inc. (CRLBF) EBT (2020 - 2026)

Cresco Labs (CRLBF) has reported EBT for 7 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 231.1% year-over-year to -$3.6 million; the trailing twelve-month figure through Jun 2026 stood at -$117.3 million (down 584.8% YoY), and the FY2025 full-year result was -$140.0 million, down 131.52% from the prior year.
• EBT declined to -$3.6 million in Q2 2026 per CRLBF's latest filing, from -$2.8 million in the prior quarter.
• Across five years, EBT topped out at $12.8 million in Q4 2023 and bottomed at -$156.9 million in Q4 2022.
• Historically, EBT has averaged -$30.6 million across 5 years, with a median of -$11.8 million in 2022.
• The widest YoY moves for EBT: up 108.17% in 2023, down 3391.69% in 2023.
• Over 5 years, EBT stood at -$156.9 million in 2022, then surged by 108.17% to $12.8 million in 2023, then sank by 76.17% to $3.1 million in 2024, then tumbled by 3011.59% to -$88.9 million in 2025, then surged by 95.96% to -$3.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.6 million, -$2.8 million, and -$88.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.